問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Infectious Disease

更新時間：2024-06-03

詹明澄Chan, Ming -Cheng
  • Principal Investigator
  • Clinical Trial Experience (year)

  • mingcheng.chan@gmail.com

Recruiting Trial

20Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

詹明澄

Taichung Veterans General Hospital

Division of Thoracic Medicine

List

39Cases

2013-06-21 - 2014-04-30

Phase III

A prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids

  • Condition/Disease

    Severe Persistent Asthma

  • Test Drug

    masitinib

Participate Sites
5Sites

Terminated5Sites

2014-09-01 - 2018-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-01-15 - 2008-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-06-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-05-01 - 2015-12-31

Phase III

A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

  • Condition/Disease

    Chronic Obstructive Pulmonary Disease (COPD)

  • Test Drug

    Fluticasone Furoate/Vilanterol

Participate Sites
5Sites

Terminated5Sites

2014-12-01 - 2017-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-06-01 - 2019-12-31

Phase II

Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia

  • Condition/Disease

    Pseudomonas Aeruginosa Pneumonia

  • Test Drug

    Aerucin（aerubumab，AR-105）

Participate Sites
11Sites

Terminated10Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

2013-08-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2006-12-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2014-09-15 - 2017-04-30

Phase II/III

A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVENOUS CEFTOLOZANE/TAZOBACTAM COMPARED WITH MEROPENEM IN ADULT PATIENTS WITH VENTILATED NOSOCOMIAL PNEUMONIA

  • Condition/Disease

    VENTILATED NOSOCOMIAL PNEUMONIA

  • Test Drug

    Ceftolozane／Tazobactam

Participate Sites
5Sites

Terminated5Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB